No Data
No Data
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Baird analyst Jack Allen maintains $Mereo BioPharma(MREO.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 32.9% and a total
Mereo BioPharma Group Plc (MREO): A Bull Case Theory
Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Mereo BioPharma CFO Sells Over $121k in Company Stock
Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference